Seven coronaviruses (CoVs) have been identified in the etiology of human infections, among which, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV) are highly pathogenic human coronaviruses (HPH-CoVs), whereas HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 belong to low pathogenic human coronaviruses (LPH-CoVs). SARS-CoV, MERS-CoV, and SARS-CoV-2 were first zoonotically transmitted to humans in 2002, 2012, and 2019, respectively, and are known to cause significant lower respiratory syndrome and severe pneumonia in humans \[[@bb0005]\]. Compared with MERS-CoV, SARS-CoV-2 is more closely related to SARS-CoV, since they both recognize angiotensin-converting enzyme 2 (ACE2) as the receptor for viral entry into the host cells \[[@bb0005]\]. Different from HPH-CoVs, the LPH-CoVs, including HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, exhibit a worldwide distribution, causing common cold in humans with mild upper respiratory tract infections \[[@bb0005]\].

Recently (in this issue), Ma *et al*. pointed out that LPH-CoV-specific antibodies (Abs) with crossreactivity against SARS-CoV-2 may have a more important impact on the global COVID-19 pandemic than HPH-CoV-specific Abs through the greater number of individuals with previous LPH-CoV infection \[[@bb0010]\]. Thus, they argue for the necessity of investigating the potential effect of LPH-CoV-specific Abs in humans on SARS-CoV-2 infection. We agree, since such study may, indeed, provide guidelines for the rational use of intravenous immunoglobulin (IVIG) and COVID-19 convalescent sera for treatment of SARS-CoV-2 infection.

HPH-CoV-Specific Abs with Crossreactivity against SARS-CoV-2 {#s0005}
============================================================

Abs against SARS-CoV have been identified with crossreactivity against SARS-CoV-2. These Abs can recognize the receptor-binding domain (RBD) in the S1 subunit of spike (S) protein of SARS-CoV-2. For example, monoclonal antibodies (mAbs), such as 18F3, 7B11, S309, and 47D11, recognize epitopes on the RBD of SARS-CoV-2 and neutralize SARS-CoV-2 infection; other mAbs, including S303, crossreact with SARS-CoV-2 RBD, but they do not neutralize its infectivity \[[@bb0015], [@bb0020], [@bb0025]\]. A few SARS-CoV S2-specific Abs, such as mAb 1A9, have even demonstrated crossreactivity with SARS-CoV-2 \[[@bb0030]\]. However, we still need to address a clinically vital question, that is, whether SARS-CoV-specific Abs can enhance SARS-CoV-2 infection. At this time, no crossreactivity between Abs against SARS-CoV-2 and MERS-CoV has been identified, partially because of low sequence homology between their S proteins and different receptors that they recognize.

LPH-CoV-Specific Abs with Crossreactivity against SARS-CoV-2 {#s0010}
============================================================

Pre-existing Abs to LPH-CoVs with crossreactivity against SARS-CoV-2 proteins have been identified \[[@bb0035],[@bb0040]\]. Patient serum IgG Abs against LPH-CoV S proteins, particularly the conserved S2 subunit, are crossreactive with SARS-CoV-2, but those targeting the S1 subunit, particularly the RBD, are mostly strain-specific with less crossreactivity against SARS-CoV-2 \[[@bb0040]\]. Still, while LPH-CoV-specific Abs with crossreactivity against SARS-CoV-2 may have beneficial effects (e.g., neutralizing SARS-CoV-2 infection), we again raise the key question of whether they might also have harmful effects (e.g., enhancing SARS-CoV-2 infection).

Potential Benefits of Pre-existing LPH-CoV-Specific Abs on SARS-CoV-2 Infection {#s0015}
===============================================================================

As mentioned earlier, the pre-existing LPH-CoV-specific Abs with crossreactivity against SARS-CoV-2 could effectively crossneutralize SARS-CoV-2 infection \[[@bb0040]\]. It appears that most of these LPH-CoV-specific Abs do not bind to the S1-RBD in SARS-CoV-2 S protein \[[@bb0040]\], which is responsible for binding of virions with the ACE2 receptor on the host cells \[[@bb0005]\]; instead, they mainly interact with the SARS-CoV-2 S2 region \[[@bb0040]\], which mediates the fusion between virions and target cell membranes ([Figure 1](#f0005){ref-type="fig"} ) \[[@bb0045]\]. Therefore, future studies should investigate the underlying mechanism(s) by which LPH-CoV-specific Abs crossneutralize SARS-CoV-2 infection.Figure 1Potential Effects of Low Pathogenic Human Coronavirus (LPH-CoV)-Specific Antibodies (Abs) on Infectivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).SARS-CoV-2 first binds to a cellular receptor, such as angiotensin-converting enzyme 2 (ACE2), on the target cells through its receptor-binding domain (RBD) in the S1 subunit of the spike (S) protein, which triggers the conformational change of the S2 subunit, resulting in virus--cell membrane fusion and viral entry into to the target cells for replication. (A) LPH-CoV-specific Abs may bind to S1 (in some cases) or S2 of SARS-CoV-2 S protein to block receptor binding or inhibit membrane fusion and entry into the target cells. (B) LPH-CoV-specific Abs with no, or low-titer, neutralizing activity against SARS-CoV-2 may also enter the host cells by binding to Fc receptor (FcR) on the cell membrane, resulting in antibody-dependent enhancement (ADE) effect on SARS-CoV-2 infection. This figure was created using BioRender (<https://biorender.com/>).Figure 1

Potential Harmful Effects of Pre-existing LPH-CoV-Specific Abs on SARS-CoV-2 Infection {#s0020}
======================================================================================

CoV nonneutralizing Abs, or even some neutralizing Abs at low neutralizing titers, may cause harmful effects. For example, some SARS-CoV S-specific neutralizing Abs could enhance SARS-CoV infection in an Fc receptor (FcR)-dependent, ACE2-independent manner \[[@bb0050]\]. Indeed, co-infection of SARS-CoV-2 and LPH-CoVs, such as HCoV-HKU1, were found in some patients positive for SARS-CoV-2 \[[@bb0035]\]. Such a phenomenon calls for efforts to establish if LPH-CoV-specific Abs with low, or no, neutralizing activity can actually cause an antibody-dependent enhancement (ADE) effect, in which Abs may enhance, rather than neutralize, SARS-CoV-2 infection, or other mechanisms ([Figure 1](#f0005){ref-type="fig"}).

Overall, in addition to Abs specific for highly pathogenic SARS-CoV with crossreactivity or crossneutralizing activity against SARS-CoV-2, LPH-CoV-specific Abs may also have neutralizing effects on SARS-CoV-2 infection. Of relevance, however, they might enhance infectivity. In such cases, clarification of their effects is essential before attempting to design any Ab-based therapy against SARS-CoV-2, such as IVIG or COVID-19 convalescent sera, for clinical use in the treatment of COVID-19 \[[@bb0055],[@bb0060]\]. Put simply, on the one hand, if pre-existing Abs in healthy individuals previously infected with an LPH-CoV (e.g., HCoV-OC43, HCoV-229E, HCoV-NL63, or HCoV-HKU1) exhibit potent crossneutralizing activity against SARS-CoV-2, then their sera or plasma may be collected for treatment of COVID-19 patients. On the other hand, if these Abs show an ADE effect, then the IVIG and COVID-19 convalescent sera containing these Abs should obviously be excluded from clinical use in treating SARS-CoV-2 infection. Therefore, testing LPH-CoV-specific Abs with ADE effects on SARS-CoV-2 infection in the IVIG and COVID-19 convalescent sera would establish a crucial benchmark before their use is allowed in clinics.
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